Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tigecycline

FDA-approved product (powder, intravenous), marketed as Tigecycline, Tygacil.

Registered studies
50+
Lab records
152
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Tigecycline
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Infection
  • Skin disease caused by bacterial infection
  • Skin disorder caused by infection
  • Soft Tissue Infections

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Tetracyclines
FDA pharmacologic class
Tetracycline-class Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01AA12; FDA class Tetracycline-class Antibacterial

Repurposing investigation

Tigecycline is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA88.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli78.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae99.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis62.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • K. pneumoniae: measured active in 152 of 152 lab records
Open Tigecycline in ChEMBL Registered studies below
Show the latest 150 of 152 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tigecycline with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study Evaluating Emergency-use Tigecycline in Subjects With Resistant Pathogens.

    NCT00205816 · start 2004-01

    Registered record
    Registry ID
    NCT00205816
    Conditions
    Bacterial Infections
    Interventions
    Tigecycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-01
    Completion
    2005-11
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infections
    InterventionTigecycline
    PhasePhase 3
    Registry statusCompleted

  • Study Evaluating Tigecycline vs Levofloxacin in Hospitalized With Community-Acquired Pneumonia

    NCT00079885 · start 2003-11

    Registered record
    Registry ID
    NCT00079885
    Conditions
    Community Acquired Pneumonia; Bacterial Pneumonia; Cross Infection
    Interventions
    tigecycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-11
    Completion
    2005-07
    Enrolment
    430

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCommunity Acquired Pneumonia; Bacterial Pneumonia; Cross Infection
    Interventiontigecycline
    PhasePhase 3
    Registry statusCompleted

  • Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA)

    NCT00079976 · start 2003-10

    Registered record
    Registry ID
    NCT00079976
    Conditions
    Gram-Positive Bacterial Infections; Staphylococcus Infections; Vancomycin Resistance; Methicillin Resistance
    Interventions
    Tigecycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-10
    Completion
    2005-06
    Enrolment
    174

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGram-Positive Bacterial Infections; Staphylococcus Infections; Vancomycin Resistance; Methicillin Resistance
    InterventionTigecycline
    PhasePhase 3
    Registry statusCompleted

  • Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects

    NCT00081744 · start 2002-11

    Registered record
    Registry ID
    NCT00081744
    Conditions
    Gram-Positive Bacterial Infections; Cross Infection
    Interventions
    Tigecycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-11
    Completion
    2004-08
    Enrolment
    850

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGram-Positive Bacterial Infections; Cross Infection
    InterventionTigecycline
    PhasePhase 3
    Registry statusCompleted

  • Study Comparing Tigecycline and Vancomycin With Aztreonam in Complicated Skin and Skin Structure Infections

    NCT00228410 · start 2002-11

    Registered record
    Registry ID
    NCT00228410
    Conditions
    Skin Diseases, Infectious
    Interventions
    Tigecycline; vancomycin with aztreonam
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-11
    Completion
    2003-12
    Enrolment
    503

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Diseases, Infectious
    InterventionTigecycline; vancomycin with aztreonam
    PhasePhase 3
    Registry statusCompleted